A previous investigation in GBM cells suggested that pro-inflammatory cytokines are released by cells treated with TTFields, promoting the short-term formation of CD8+ effector T cells in mice inoculated with the TTFields-treated cells, and long-term elevation in central memory T cells (CD44+CD62L+) [25]. The gene discussed is CD44; the disease is glioblastoma.